Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab Versus Chemoimmunotherapy and Other Novel Combinations in First-Line Chronic Lymphocytic Leukemia in Canada

被引：1
|
作者：
Chatterjee, Anuja
Van de Wetering, Gijs
Goeree, Ron
Desbois, Anne Marie
Manzi, Patricia
Manzoor, Beenish S.
Owen, Carolyn
Sail, Kavita
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134596
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States
    Davids, Matthew S.
    Chatterjee, Anuja
    Ravelo, Arliene
    Shapouri, Sheila
    Manzoor, Beenish S.
    Sail, Kavita
    Van de Wetering, Gijs
    Hallek, Michael
    BLOOD, 2019, 134
  • [2] A PROBABILISTIC COST-EFFECTIVENESS ANALYSIS OF VENETOCLAX AND OBINUTUZUMAB AS A FIRST-LINE, 12-MONTH, FIXED DURATION THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN CANADA
    Chatterjee, A.
    van de Wetering, G.
    Goeree, R.
    Owen, C.
    Barakat, S.
    Manzoor, B. S.
    Sail, K.
    VALUE IN HEALTH, 2022, 25 (07) : S337 - S337
  • [3] Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States
    Chatterjee, Anuja
    Shapouri, Sheila
    Manzoor, Beenish S.
    Ravelo, Arliene
    Sail, Kavita
    Qendri, Venetia
    van de Wetering, Gijs
    Davids, Matthew S.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (11): : 1532 - 1544
  • [4] A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada
    Anuja Chatterjee
    Gijs van de Wetering
    Ron Goeree
    Carolyn Owen
    Anne Marie Desbois
    Stephane Barakat
    Beenish S. Manzoor
    Kavita Sail
    PharmacoEconomics - Open, 2023, 7 : 199 - 216
  • [5] A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada
    Chatterjee, Anuja
    van de Wetering, Gijs
    Goeree, Ron
    Owen, Carolyn
    Desbois, Anne Marie
    Barakat, Stephane
    Manzoor, Beenish S.
    Sail, Kavita
    PHARMACOECONOMICS-OPEN, 2023, 7 (02) : 199 - 216
  • [6] COST-EFFECTIVENESS OF VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN FIRST LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN COLOMBIA
    Ordonez, J.
    Quitian, D.
    VALUE IN HEALTH, 2021, 24 : S29 - S29
  • [7] Cost-effectiveness of a 24-month fixed duration of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia
    Bennison, Craig
    Durno, Nicholas
    Sail, Kavita
    Alexiou, Dimitra
    Mato, Anthony
    Eyre, Toby
    Follows, George
    LEUKEMIA & LYMPHOMA, 2020, 61 : 153 - 155
  • [8] Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View
    Do, Ngoc
    Thielen, Frederick W.
    VALUE IN HEALTH, 2023, 26 (04) : 477 - 486
  • [9] Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
    Cho, Sang Kyu
    Manzoor, Beenish S.
    Sail, Kavita R.
    Parise, Helene
    Ravelo, Arliene
    Shapouri, Sheila
    Kapustyan, Tatyana
    Sharmokh, Simon
    Virabhak, Suchin
    Davids, Matthew S.
    Johnson, Scott
    PHARMACOECONOMICS, 2020, 38 (09) : 941 - 951
  • [10] Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
    Sang Kyu Cho
    Beenish S. Manzoor
    Kavita R. Sail
    Hélène Parisé
    Arliene Ravelo
    Sheila Shapouri
    Tatyana Kapustyan
    Simon Sharmokh
    Suchin Virabhak
    Matthew S. Davids
    Scott Johnson
    PharmacoEconomics, 2020, 38 : 941 - 951
12345